.

Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion

LAUR Repository

Show simple item record

dc.contributor.author Ghazi, Nicola
dc.contributor.author Boureddine, Baha'
dc.contributor.author Haddad, Randa S.
dc.contributor.author Jurdi, Fadi A.
dc.contributor.author Bashshur, Ziad F.
dc.date.accessioned 2019-06-13T09:30:01Z
dc.date.available 2019-06-13T09:30:01Z
dc.date.copyright 2003 en_US
dc.identifier.issn 1539-2864 en_US
dc.identifier.uri http://hdl.handle.net/10725/10797
dc.description.abstract Purpose To evaluate the role of intravitreal tissue plasminogen activator (tPA) in the management of central retinal vein occlusion (CRVO) in patients with symptoms for <3 days. Methods We evaluated the visual outcome of a consecutive series of patients with CRVO following intravitreal tPA injection. All patients presented with visual acuity worse than 20/50 within 3 days from the onset of symptoms. Main outcome measures included percentage of patients whose final vision improved to 20/50 or better and change in percentage of patients with vision of 20/200 or worse before and after treatment. Results Twelve patients received intravitreal tPA for CRVO. Nine patients (75%) had best-corrected visual acuity of 20/200 or worse at presentation compared with 4 patients (33%) at the last follow-up after treatment. Five (55%) of these 9 patients had final visual acuity that improved to 20/50 or better. The remaining four patients did not have improvement or their vision continued to worsen. All 4 patients had fluorescein angiographic evidence of >10 disk areas of capillary nonperfusion at presentation. Overall, 8 (67%) of 12 patients had final visual acuity of 20/50 or better. No side effects related to tPA injection were observed. Conclusion Our data suggest that intravitreal tPA injection may have a beneficial role in the management of CRVO when used within a few days of the onset of symptoms in patients with no angiographic evidence of severe capillary nonperfusion even if initial visual acuity is 20/200 or worse. en_US
dc.language.iso en en_US
dc.title Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201000154 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Retina en_US
dc.journal.volume 23 en_US
dc.journal.issue 6 en_US
dc.article.pages 780-784 en_US
dc.identifier.ctation Ghazi, N. G., BAHA’N, N. O. U. R. E. D. D. I. N. E., Haddad, R. S., Jurdi, F. A., & Bashshur, Z. F. (2003). Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion. Retina, 23(6), 780-784. en_US
dc.author.email nicola.ghazi@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://oce.ovid.com/article/00006982-200312000-00006/HTML en_US
dc.author.affiliation Lebanese American University en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR


Advanced Search

Browse

My Account